AXL
ENSG00000167601
Target class
Kinase
Chromosome
19
Approved drugs
2
Clinical candidates (approved and in development)
7
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Target name
- AXL
- Gene name
- AXL receptor tyrosine kinase
- Gene symbol
- AXL
- Protein name
- Tyrosine-protein kinase receptor UFO (EC 2.7.10.1) (AXL oncogene)
- UFO
- JTK11
- Tyro7
- ARK
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|Fibronectin type III domain containing|V-set domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 218.55
- Tissue specificity (Gini)
- 0.506
- Tissue specificity (tau)
- 0.836
- KEGG gene identifiers
- hsa:558
- Protein interaction confidence
- 0.845774
- Protein interaction partners
- 31
- R-HSA-4420097
- R-HSA-9918485
- End position
- 41261766
- Start position
- 41219174
- Chromosome
- 19
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein .
- Actin filaments
- Plasma membrane
- Vesicles
- PubMed 28076778
- PubMed 29379210
- PubMed 7896447
- Tissue specificity (tau)
- 0.836452
- Expression inequality (Gini)
- 0.505675
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 218.55
- Artery - Tibial
- 142.42
- Artery - Coronary
- 100
- Artery - Aorta
- 92.13
- Cervix - Endocervix
- 91.22
Expression in transcripts per million
- Cells - Cultured fibroblasts218.55
- Artery - Tibial142.42
- Artery - Coronary100
- Artery - Aorta92.13
- Cervix - Endocervix91.22
- Adipose - Subcutaneous81.9
- Nerve - Tibial80.46
- Colon - Sigmoid79.93
- Cervix - Ectocervix78.73
- Esophagus - Gastroesophageal Junction75.36
- Uterus72.74
- Esophagus - Muscularis69.34
- Fallopian Tube68.06
- Bladder62.22
- Adipose - Visceral (Omentum)53.19
- Breast - Mammary Tissue49.72
- Vagina47.59
- Lung46.46
- Ovary43.72
- Colon - Transverse38.5
- Thyroid36.22
- Prostate36.21
- Testis35.84
- Spleen35.84
- Skin - Sun Exposed (Lower leg)34.02
And 29 more, listed on the interactive page.
- GO:0001961
- GO:0006909
- GO:0007165
- GO:0032689
- GO:0032825
- GO:0035457
- GO:0046718
- GO:0048010
- GO:0048469
- GO:0048549
- GO:0071222
- GO:0097028
- GO:1903902
- GO:2000669
- GO:0005576
- GO:0005886
- GO:0009986
- GO:0010008
- GO:0070062
- GO:0001618
- GO:0001786
- GO:0004713
- GO:0004714
- GO:0005515
Related records
Trials (100)
- A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
- A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
- A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
- A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
- A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
- A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Drugs (7)
- Bemcentinib Tyrosine-protein kinase receptor UFO inhibitor
- BPI-9016 Tyrosine-protein kinase receptor UFO inhibitor
- Enapotamab vedotin Tyrosine-protein kinase receptor UFO binding agent
- Gilteritinib Tyrosine-protein kinase receptor UFO inhibitor
- Gilteritinib fumarate Tyrosine-protein kinase receptor UFO inhibitor
- Mecbotamab vedotin Tyrosine-protein kinase receptor UFO binding agent
- Ningetinib Tyrosine-protein kinase receptor UFO inhibitor